Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of treating fibrosis, cancer and vascular injuries

a fibrosis and cancer technology, applied in the field of fibrosis, cancer and vascular injuries, can solve problems such as complicated organ transplantation, and achieve the effects of reducing the number of patients, preventing and treating various disease states, and facilitating the transplantation

Active Publication Date: 2018-11-27
EWHA UNIV IND COLLABORATION FOUND
View PDF11 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes the discovery of a new group of compounds that can inhibit the activity of two proteins (ALK5 and ALK4) involved in various disease states such as kidney disease, diabetic nephropathy, and liver fibrosis. These compounds have potential to be developed into drugs for the treatment of these diseases. The patent text also mentions that these compounds can be used to treat other conditions such as heart disease, glaucoma, and skin scarring.

Problems solved by technology

Organ transplantation is complicated in many instances by chronic rejection and for some organs such as the kidney, it is the major forms of graft loss.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating fibrosis, cancer and vascular injuries
  • Methods of treating fibrosis, cancer and vascular injuries
  • Methods of treating fibrosis, cancer and vascular injuries

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0215 suppressed TGF-β1-induced cell migration in MCF10A cells.

[0216]Matrigel Invasion Assay

[0217]The upper surface of Transwells (6.5 mm diameter, 8 μm pore size; Corning, Lowell, Mass., USA) were coated with 20 μL diluted Matrigel (BD Biosciences). 4T1 cells were seeded at 4×104 cells / well on the upper chamber of transwell in serum free medium with or without TGF-β1 (2 ng / mL) in the presence or absence of Example 2. The lower chamber was filled with 10% FBS with TGF-β1 (2 ng / mL) in the presence or absence of Example 2. After incubation for 20 h at 37° C. in 5% CO2, the cells remaining on the upper surface of the membrane were removed with a cotton swab, and DAPI-stained cells remaining on the bottom surface were observed using fluorescence microscopy. Average cell number per view field was obtained from 5 random fields.

[0218]Example 2 suppressed TGF-β1-induced cell invasion in matrigel invasion assay.

[0219]Cell Growth Study

[0220]Either 4T1 cells or MCF10A cells were seeded in 96-w...

example 61

[0228 significantly reduced the number of metastastic lesions in the lung. Significant level of β-casein (a mammary differentiation marker) mRNA was detected in the lung of MMTV / c-Neu mice. Examples 3 and 61 significantly inhibited β-casein mRNA expression level in the lung, demonstrating their anti-metastatic effect.

[0229]Activity of MMP-9 and MMP-2 in the primary mammary tumor was measured by gelatin zymography. Tumor tissues from mice (30 mg) was lysed in 500 μL RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% NP-40, protease inhibitor without EDTA) for 10-20 min on ice. Lysates were cleared by centrifugation at 13000 rpm at 4° C. for 10 min. Protein content of supernatants was determined using Micro-BCA protein assay kit (Thermo Scientific). Loading samples were prepared by adding loading buffer (0.5 M Tris, pH 6.8, 50% glycerol, 10% SDS, and 1% bromophenol blue solution) into lysates containing 15 μg of total protein. Loading sampl...

example 3

[0230 significantly inhibited activity of MMP-9 and MMP-2 in the primary mammary tumor.

[0231]Anti-Fibrotic Effect on Bile Duct-Ligated Liver Fibrosis Model

[0232]Six-week-old male Sprague-Dawley (SD) rats were purchased from Orient Bio Inc. In Experiment 1, SD rats weighing 180-200 g were randomly divided into five experimental groups: sham-operated control rats (n=5), sham-operated rats treated with Example 3 (43.6 mg / kg, n=5), bile duct-ligated (BDL) rats (n=10), BDL rats treated with either 21.8 or 43.6 mg / kg of Example 3 (n=10). In Experiment 2, SD rats weighing 180-200 g were randomly divided into five experimental groups: sham-operated control rats (n=5), BDL rats (n=10), BDL rats treated with either 5, 10, or 20 mg / kg of Example 2 (n=10). For BDL, the animals were anesthetized with zoletil (20 mg / kg) and xylazine (10 mg / kg), and the common bile duct was exposed and double-ligated using 3-0 silk. The first ligature was placed below the junction of the hepatic duct, and the seco...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightsaaaaaaaaaa
molecular weightsaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

This invention relates to use of inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and / or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.

Description

[0001]This application is a continuation-in-part of U.S. patent application Ser. No. 12 / 826,338 filed Jun. 29, 2010 entitled “2-Pyridyl Substituted Imidazoles as Therapeutic ALK5 and / or ALK 4 Inhibitors”, the disclosure of which is incorporated herein by reference.[0002]This application is a reissue of U.S. Pat. No. 8,513,222 B2, which issued from U.S. patent application Ser. No. 13 / 168,342, filed on Jun. 24, 2011.TECHNICAL FIELD OF THE INVENTION[0003]This invention relates to use of inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and / or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.BACKGROUND OF THE INVENTION[0004]TGF-β denotes a family of proteins, TGF-β1, TGF-β2 and TGF-β3, which are pleiotropic modulators of cell proliferation and differentiation, wound healing, extracellular matrix production, and immunosuppression. Other members of this superfamily include activins, inhibins, bone m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K31/437A61K31/5377C07D471/04
CPCA61K31/5377A61P35/00A61K31/444A61P1/16A61P11/00A61K31/437
Inventor KIM, DAE-KEESHEEN, YHUN YHONGJIN, CHENGHUAPARK, CHUL-YONGDOMALAPALLY, SREENUKOTA, SUDHAKAR RAOMADDEBOINA, KRISHNAIAHVURA BALA, SUBRAHMANYAM
Owner EWHA UNIV IND COLLABORATION FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com